All CMVD dogs underwent the above evaluation at baseline (T0) and after 3 (T1) and 6 (T2) months.
The characteristics of the 36 CMVD dogs were compared with those of the healthy dogs (Table 1).
In the present study, the use of carvedilol and a regimen of supervised aerobic training improved functional class, the FETCH score and quality of life, and stabilized the NT-proBNP level in the CMVD dogs.
The characteristics of the CMVD dogs with regard to NT-proBNP, NE, troponin I, and sodium values were significantly higher than those in the healthy dogs, and were similar to those that have been reported in previous studies (2,11,25,26).
Treatment of the CMVD dogs with carvedilol did not improve survival, regardless of the dosage used and whether or not its use was combined with physical exercise; this is similar to previous reports of dogs treated with the angiotensin-converting enzyme inhibitor benazepril for 6 months, and in humans with heart failure (13,29,30).
Our results suggest that an individual carvedilol dose may be used to treat CMVD dogs.
Some authors have related the intercurrences to the inotropic and negative chronotropic actions of carvedilol, and have recommended its addition to the treatment regimen for CMVD dogs already stabilized on other heart failure medications (8,27,36).
So light walking for CMVD dogs should be encouraged at least two to three times a week for about 20 to 30 min.
In conclusion, the association of carvedilol or exercise training with conventional treatment in CMVD dogs led to improvements in quality of life and functional class.